放疗联合贝伐珠单抗对比单纯放疗治疗复发高级别胶质瘤的系统综述
本系统综述纳入1399例复发高级别胶质瘤患者,比较再程放疗联合或不联合贝伐珠单抗的疗效。
要点
- 再程放疗联合贝伐珠单抗可显著改善复发高级别胶质瘤患者的总生存期。
- 联合贝伐珠单抗显著降低放射性坏死发生率(2.2% vs 6.5%)。
- 无进展生存期未见显著获益,需进一步对照研究确认。
核心结论
- 再程放疗联合贝伐珠单抗可能改善复发高级别胶质瘤的总生存期并降低放射性坏死率。
- 联合治疗对无进展生存期的改善无统计学意义。
研究设计与样本
- 系统综述遵循PRISMA指南,检索PubMed、Web of Science、Scopus、Embase和Cochrane数据库。
- 共分析1399例复发高级别胶质瘤患者,其中954例接受单纯再程放疗,445例接受再程放疗联合贝伐珠单抗。
- 按贝伐珠单抗使用状态和再程放疗模式(立体定向放射外科、大分割放射外科、常规分割放疗)进行分层。
临床怎么用
- 对于复发高级别胶质瘤患者,再程放疗联合贝伐珠单抗可考虑用于改善总生存期和降低放射性坏死风险。
- 需注意无进展生存期未见显著获益,治疗决策应个体化并结合进一步对照研究证据。
局限性
- 作者指出需要进一步对照研究来确认联合治疗的效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-grade gliomas (HGG) comprise the most common primary adult brain cancers and universally recur. Combination of re-irradiation therapy (reRT) and bevacizumab (BVZ) therapy for recurrent HGG is common, but its reported efficacy is mixed. OBJECTIVE: To assess clinical outcomes after reRT ± BVZ in recurrent HGG patients receiving stereotactic radiosurgery (SRS), hypofractionated radiosurgery (HFSRT), or fully fractionated radiotherapy (FFRT). METHODS: We performed a systematic review of PubMed, Web of Science, Scopus, Embase, and Cochrane databases, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We identified studies reporting outcomes for patients with recurrent HGG treated via reRT ± BVZ. Cohorts were stratified by BVZ treatment status and re-irradiation modality (SRS, HFSRT, and FFRT). Outcome variables were overall survival (OS), progression-free survival (PFS), and radiation necrosis (RN). RESULTS: Data on 1399 patients was analyzed, with 954 patients receiving reRT alone and 445 patients receiving reRT + BVZ. All patients initially underwent standard-of-care therapy for their primary HGG. In a multivariate analysis that adjusted for median patient age, WHO grade, RT dosing, reRT fractionation regimen, time between primary and re-irradiation, and re-irradiation target volume, BVZ therapy was associated with significantly improved OS (2.51, 95% CI [0.11, 4.92] months, P = .041) but no significant improvement in PFS (1.40, 95% CI [- 0.36, 3.18] months, P = .099). Patients receiving BVZ also had significantly lower rates of RN (2.2% vs 6.5%, P < .001). CONCLUSIONS: Combination of reRT + BVZ may improve OS and reduce RN rates in recurrent HGG, but further controlled studies are needed to confirm these effects.
引用
- Kulinich DP, Sheppard JP, Nguyen T, et al. Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review. Acta Neurochir (Wien). 2021. PMID: 33796887. doi:10.1007/s00701-021-04794-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。